BridgeBio CEO executes $5.5M stock sale amid drug trial progress
BridgeBio Pharma Chief Executive Kumar Neil, acting through trusts where he is co-trustee, sold 70,185 shares of common stock on March 12 and 13, 2026 under a pre-arranged Rule 10b5-1 trading plan, generating roughly $5.5 million in proceeds. The transactions come as BBIO shares have risen 115% over the past year and follow positive interim Phase 3…